BioStock interviews Christina Herder new CEO in Idogen
Idogen AB (publ) is a company developing tolerogenic cell therapies to treat conditions or diseases caused by an unwanted immune response in the patient. The candidate drug ItolDC-028 will within short be tested for the first time in patients with haemophilia who have developed antibodies against their vital factor VIII treatment. The aim is to make the patients responsing again to their factor VIII treatment. Christina Herder took office as acting CEO on September 1 and is giving her first interview with BioStock. During the autumn, Christina is expecting a number of key events